Frontiers in Immunology (May 2024)

Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival

  • Anke Mittelstädt,
  • Anna Anthuber,
  • Paul David,
  • Malgorzata Podolska,
  • Alan Bénard,
  • Maximilian Brunner,
  • Christian Krautz,
  • Anne Jacobsen,
  • Axel Denz,
  • Klaus Weber,
  • Susanne Merkel,
  • Danilo Hackner,
  • Timur Buniatov,
  • Lotta Roßdeutsch,
  • Bettina Klösch,
  • Izabella Swierzy,
  • Frederik J. Hansen,
  • Deike Strobel,
  • Yurdagül Zopf,
  • Jan-Ole Baur,
  • Jan Van Deun,
  • Carol Immanuel Geppert,
  • Andreas Gießl,
  • Sebastian Lettmaier,
  • Sabine Semrau,
  • Robert Grützmann,
  • Robert Grützmann,
  • Robert Grützmann,
  • Dina Kouhestani,
  • Georg F. Weber,
  • Georg F. Weber,
  • Georg F. Weber

DOI
https://doi.org/10.3389/fimmu.2024.1253072
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer and peritoneal dissemination is one major cause for this poor prognosis. Exosomes have emerged as promising biomarkers for gastrointestinal cancers and can be found in all kinds of bodily fluids, also in peritoneal fluid (PF). This is a unique sample due to its closeness to gastrointestinal malignancies. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) has been identified as a potential biomarker in human cancers and represents a promising target for an immunotherapy approach, which could be considered for future treatment strategies. Here we prospectively analyzed the exosomal surface protein ROR1 (exo-ROR1) in PF in localized PDAC patients (PER-) on the one hand and peritoneal disseminated tumor stages (PER+) on the other hand followed by the correlation of exo-ROR1 with clinical-pathological parameters.MethodsExosomes were isolated from PF and plasma samples of non-cancerous (NC) (n = 15), chronic pancreatitis (CP) (n = 4), localized PDAC (PER-) (n = 18) and peritoneal disseminated PDAC (PER+) (n = 9) patients and the surface protein ROR1 was detected via FACS analysis. Additionally, soluble ROR1 in PF was analyzed. ROR1 expression in tissue was investigated using western blots (WB), qPCR, and immunohistochemistry (IHC). Exosome isolation was proven by Nano Tracking Analysis (NTA), WB, Transmission electron microscopy (TEM), and BCA protein assay. The results were correlated with clinical data and survival analysis was performed.ResultsPDAC (PER+) patients have the highest exo-ROR1 values in PF and can be discriminated from NC (p <0.0001), PDAC (PER-) (p <0.0001), and CP (p = 0.0112). PDAC (PER-) can be discriminated from NC (p = 0.0003). In plasma, exo-ROR1 is not able to distinguish between the groups. While there is no expression of ROR1 in the exocrine pancreatic tissue, PDAC and peritoneal metastasis show expression of ROR1. High exo-ROR1 expression in PF is associated with lower overall survival (p = 0.0482).ConclusionWith exo-ROR1 in PF we found a promising diagnostic and prognostic biomarker possibly discriminating between NC, PDAC (PER-) and PDAC (PER+) and might shed light on future diagnostic and therapeutic concepts in PDAC.

Keywords